Video

Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced Melanoma

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

Grant McArthur, PhD, Melanoma Unit, Peter MacCallum Cancer Centre, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib (Cotellic) plus vemurafenib (Zelboraf) in patients with BRAF V600-mutated advanced melanoma.

In an analysis of subpopulations, McArthur says all patients did receive benefit from the combination versus monotherapy treatment. However, patients with an elevated lactate dehydrogenase (LDH) had less benefit in terms of long-term survival outcomes. Forty-three percent of patients with a normal LDH at baseline were alive at 5 years, while 16% with an elevated LDH remained alive. This is a striking difference, McArthur notes.

Related Videos
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School